XOMA Royalty Corp
OJEMDA
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews OJEMDA for its lead indication around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 8-K
verified 13h ago
“Potential for EMA decisions on OJEMDA ™ and MIPLYFFA ™ marketing authorization applications”